Josh Bilenker, Eli Lilly cancer chief (JPM 2020)
Eli Lilly is betting $1B-plus that it can make yet another PD-1 drug a hit in the US. How about a deep discount this time?
Eli Lilly is importing an anti-PD-1 therapy from China with plans for a quick march to the FDA. And the pharma giant is willing to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
